title: Intravitreal bevacizumab for choroidal neovascularization secondary to Best vitelliform macular dystrophy in a 6-year-old child.
abstract: OBJECTIVE
  To report a young patient with choroidal neovascularization (CNV) secondary to Best vitelliform macular dystrophy (BVMD) who recovered good visual acuity with intravitreal bevacizumab (IVB).
  
  
  METHODS
  A 6-year-old boy was noted to have diminution of vision in both eyes. His best-corrected visual acuity (BCVA) was 20/40 in the right eye (OD) and 20/160 in the left eye (OS). Detailed examination including slit-lamp biomicroscopy, fluorescein angiography, and optical coherence tomography (OCT) showed active CNV in OS. Two consecutive IVB injections (1.25 mg/0.05 mL) were given in OS.
  
  
  RESULTS
  During the follow-up, OD showed minimal subretinal fluid on OCT and was treated with one injection of IVB (1.25 mg/0.05 mL). At 9 months of follow-up, OS BCVA was 20/50 and OD BCVA 20/30 with presence of scarred CNV on fundus examination and OCT in both the eyes. No drug-related ocular or systemic side effects were encountered.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab appears to be a promising and cost-effective modality of treatment in CNV associated with BVMD with good visual recovery.
authors.affiliation: LV Prasad Eye Institute, Hyderabad, India. jay.chhablani@gmail.com
authors.forename: Jay
authors.initials: J
authors.lastname: Chhablani
authors.forename: Subhadra
authors.initials: S
authors.lastname: Jalali
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D002648:Child; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D057826:Vitelliform Macular Dystrophy / Q000150:complications*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab